TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients. 

¿El TAVI en válvulas bicúspides presenta mayor mismatch protésico?

The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of echocardiograms and autopsies. We know this is a challenging anatomy for TAVR, because of greater calcification, which has been associated to increased complications and even higher mortality in the midterm, in some registries. Another potential issue is prosthetic mismatch (PPM), linked to worse evolution at long term. 

This analysis of the OCEAN TAVI registry included 7,051 patients, 503 (7.13%) presenting BAV aortic stenosis (AS), and the rest a tricuspid aortic valve (TAV) AS. Balloon expandable (BEV) Sapien XT and Sapien 3, and self-expanding valves (SEV) CoreValve and Evolut R/PRO were used. 

Read also: ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions.

The heterogeneous groups were matched using propensity score, leaving 497 in each one. Mean patient age was 84, over 60% were women, mortality STS was 6%, 62% presented hypertension, 22% diabetes, 15% atrial fibrillation, and 67% kidney function deterioration. 

The transfemoral approach was used in 97% of cases, with no differences in type or valve diameter; the most used in both groups was the 29 mm valve. During the procedure, major and minor bleeding were more frequent among TAV patients (7.2% vs. 3%, p=0.003; 6% vs. 2.2%, p=0.002, respectively). There were no differences in aortic root lesion, coronary obstruction, conversion to surgery, stroke, life threatening bleeding, vascular complications or need for pacemaker implantation. Hospital stay was similar. 

At 30 days, mortality was 1% in both groups. 

Read also: Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation.

At two year followup, there were no differences in mortality, effective aortic area, indexed area, peak velocity or mean gradient. However, the presence of PPM was higher among TAV patients (moderate PPM 11.7% vs. 4.4%, severe 1.4% vs. 1%; p=0.001). PPM seemed associated to higher mortality, though with no statistical significance (p=0.065), and in the propensity score matched population, there was no significant impact (p=0.90).

Conclusion

Severe prosthetic mismatch could be associated to all-cause mortality, However, moderate and severe prosthetic mismatch was more frequent in patients with tricuspid aortic stenosis, vs bicuspid. 

Original Title: Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis

Reference: Futoshi Yamanaka, et al. JACC Cardiovasc Interv. 2025;18:492–502.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...